Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Chicago Capital LLC

Chicago Capital LLC increased its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 0.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,583 shares of the biotechnology company’s stock after acquiring an additional 45 shares during the quarter. Chicago Capital LLC’s holdings in Axon Enterprise were worth $8,625,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its position in shares of Axon Enterprise by 7.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 75,201 shares of the biotechnology company’s stock valued at $30,050,000 after purchasing an additional 5,218 shares during the period. Friedenthal Financial purchased a new stake in Axon Enterprise during the third quarter valued at about $51,000. Blue Trust Inc. lifted its stake in Axon Enterprise by 234.5% during the third quarter. Blue Trust Inc. now owns 291 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 204 shares in the last quarter. Stratos Wealth Advisors LLC purchased a new position in shares of Axon Enterprise in the third quarter worth approximately $259,000. Finally, CHB Investment Group LLC acquired a new stake in shares of Axon Enterprise during the third quarter valued at approximately $3,626,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at $1,121,052,771.48. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the transaction, the director now owns 26,259 shares in the company, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 80,300 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at $1,121,052,771.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 371,172 shares of company stock valued at $137,000,162. Insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Performance

AXON stock opened at $438.05 on Friday. The firm has a 50 day moving average of $388.71 and a two-hundred day moving average of $331.79. Axon Enterprise, Inc. has a 12 month low of $199.29 and a 12 month high of $440.89. The company has a market capitalization of $33.10 billion, a price-to-earnings ratio of 115.58, a P/E/G ratio of 11.74 and a beta of 0.94. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the company posted $0.80 earnings per share. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Robert W. Baird raised their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Jefferies Financial Group began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price for the company. Barclays upped their price target on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities raised their price objective on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Northland Securities upped their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.